[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[2]
|
Vernieri, C., Milano, M., Brambilla, M., Mennitto, A., Maggi, C., Cona, M.S., Prisciandaro, M., Fabbroni, C., Celio, L., Mariani, G., Bianchi, G.V., Capri, G. and de Braud, F. (2019) Resistance Mechanisms to Anti-HER2 Therapies in HER2-Positive Breast Cancer: Current Knowledge, New Research Directions and Therapeutic Perspectives. Critical Reviews in Oncology/Hematology, 139, 53-66. https://doi.org/10.1016/j.critrevonc.2019.05.001
|
[3]
|
Martin, M., Holmes, F.A., Ejlertsen, B., et al. (2017) Nerat-inib after Trastuzumab-Based Adjuvant Therapy in HER-2 Positive Breast Cancer (ExteNET): 5-Year Analysis of a Randomised, Double Blind, Placebo-Controlled, Phase 3 Trim. The Lancet Oncology, 18, 1688-1700. https://doi.org/10.1016/S1470-2045(17)30717-9
|
[4]
|
Ellis, P.A., Barrios, C.H., Eiermann, W., et al. (2015) Phase III, Randomized Study of Trastuzumab Emtansine (T -DMI) ± Pertuzumab (P) vs Trastuzumab + Taxane(HT) for First-Line Treatment of HER2-Positive MBC: Primary Results from the MARIANNE Study. Journal of Clinical On-cology, 33, 507.
https://doi.org/10.1200/jco.2015.33.15_suppl.507
|
[5]
|
Cardoso, F., Kyriakides, S., Ohno, S., et al. (2019) Early Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Journal of Clinical Oncol-ogy, 30, 1194-220. https://doi.org/10.1093/annonc/mdz173
|
[6]
|
Cardoso, F., Senkus, E., Costa, A., et al. (2018) 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Annals of Oncology, 29, 1634-1657. https://doi.org/10.1093/annonc/mdy192
|
[7]
|
Le, X.F., Pruefer, F. and Bast Jr., R.C. (2005) HER2-Targeting Antibodies Modulate the Cyclin-Dependent Kinase Inhibitor p27Kip1 via Multiple Signaling Pathways. Cell Cycle, 4, 87-95. https://doi.org/10.4161/cc.4.1.1360
|
[8]
|
Austin, C.D., De Maziere, A.M., Pisacane, P.I., van Dijk, S.M., Eigenbrot, C., Sliwkowski, M.X., Klumperman, J. and Scheller, R.H. (2004) Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin. Molecular Biology of the Cell, 15, 5268-5282. https://doi.org/10.1091/mbc.e04-07-0591
|
[9]
|
Collins, D.M., O’Donovan, N., McGowan, P.M., O’Sullivan, F., Duffy, M.J. and Crown, J. (2012) Trastuzumab Induces Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) in HER-2-Non-Amplified Breast Cancer Cell Lines. Annals of Oncology, 23, 1788-1795. https://doi.org/10.1093/annonc/mdr484
|
[10]
|
Osoba, D., Slamon, D.J., Burchmore, M. and Murphy, M. (2002) Ef-fects on Quality of Life of Combined Trastuzumab and Chemotherapy in Women with Metastatic Breast Cancer. Journal of Clinical Oncology, 20, 3106-3113.
https://doi.org/10.1200/JCO.2002.03.090
|
[11]
|
Xu, Y., Benlimame, N., Su, J., He, Q. and Alaoui-Jamali, M.A. (2009) Regulation of Focal Adhesion Turnover by ErbB Signalling in Invasive Breast Cancer Cells. British Journal of Cancer, 100, 633-643.
https://doi.org/10.1038/sj.bjc.6604901
|
[12]
|
Petit, A.M., Rak, J., Hung, M.C., Rockwell, P., Goldstein, N., Fendly, B. and Kerbel, R.S. (1997) Neutralizing Antibodies against Epidermal Growth Factor and ErbB-2/neu Receptor Tyrosine Kinases Downregulate Vascular Endothelial Growth Factor Production by Tumor Cells in Vitro and in Vivo: Angiogenic Implications for Signal Transduction Therapy of Solid Tumors. Am. J. Pathol, 151, 1523-1530.
|
[13]
|
Sorace, A.G., Quarles, C.C., Whisenant, J.G., Hanker, A.B., McIntyre, J.O., Sanchez, V.M. and Yankeelov, T.E. (2016) Trastuzumab Improves Tumor Perfusion and Vascular Delivery of Cytotoxic Therapy in a Murine Model of HER2+ Breast Cancer: Preliminary Results. Breast Cancer Research and Treatment, 155, 273-284.
https://doi.org/10.1007/s10549-016-3680-8
|
[14]
|
王慧, 赵安帝, 杨谨. 曲妥珠单抗联合帕妥珠单抗用于HER2阳性早期乳腺癌研究进展[J]. 华中科技大学学报(医学版), 2020, 49(1): 111-116.
|
[15]
|
韩萌萌, 冯雪园, 马宁. 人表皮生长因子受体2阳性乳腺癌的靶向治疗研究进展[J]. 中华普通外科学文献(电子版), 2021, 15(6): 453-458.
|
[16]
|
Wang, Q., Zhang, X., Shen, E., Gao, J., Cao, F., Wang, X., Li, Y., Tian, T., Wang, J., Chen, Z., Wang, J. and Shen, L. (2016) The Anti-HER3 Antibody in Combination with Trastuzumab Exerts Synergistic Antitumor Activity in HER2- Positive Gastric Cancer. Cancer Letters, 380, 20-30. https://doi.org/10.1016/j.canlet.2016.06.005
|
[17]
|
Slamon, D.J., et al. (1989) Studies of the HER-2/neu Protoonco-gene in Human Breast and Ovarian Cancer. Science, 244, 707-712. https://doi.org/10.1126/science.2470152
|
[18]
|
Wolff, A.C., et al. (2013) Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Journal of Clinical Oncology, 31, 3997-4013. https://doi.org/10.1200/JCO.2013.50.9984
|
[19]
|
Rimawi, M.F., Schiff, R. and Osborne, C.K. (2015) Targeting HER2 for the Treatment of Breast Cancer. Annual Review of Medicine, 66, 111-128. https://doi.org/10.1146/annurev-med-042513-015127
|
[20]
|
Moasser, M.M. (2007) The Oncogene HER2: Its Sig-naling and Transforming Functions and Its Role in Human Cancer Pathogenesis. Oncogene, 26, 6469-6487. https://doi.org/10.1038/sj.onc.1210477
|
[21]
|
Goutsouliak, K., Veeraraghavan, J., Sethunath, V., De Angelis, C., Osborne, C.K., Rimawi, M.F. and Schiff, R. (2020) Towards Personalized Treatment for Early Stage HER2-Positive Breast Cancer. Nature Reviews Clinical Oncology, 17, 233-250. https://doi.org/10.1038/s41571-019-0299-9
|
[22]
|
Clynes, R.A., Towers, T.L., Presta, L.G. and Ravetch, J.V. (2000) Inhibitory Fc Receptors Modulate in Vivo Cytotoxicity against Tumor Targets. Nature Medicine, 6, 443-446. https://doi.org/10.1038/74704
|
[23]
|
Goutsouliak, K., Veeraraghavan, J., Sethunath, V., De Angelis, C., Osborne, C.K., Rimawi, M.F. and Schiff, R. (2020) Towards Personalized Treatment for Early Stage HER2-Positive Breast Cancer. Nature Reviews Clinical Oncology, 17, 233-250. https://doi.org/10.1038/s41571-019-0299-9
|
[24]
|
Scheuer, W., et al. (2009) Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models. Cancer Research, 69, 9330-9336.
https://doi.org/10.1158/0008-5472.CAN-08-4597
|
[25]
|
Yamashita-Kashima, Y., et al. (2011) Pertuzumab in Com-bination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models. Clinical Cancer Research, 17, 5060- 5070. https://doi.org/10.1158/1078-0432.CCR-10-2927
|
[26]
|
Gianni, L., et al. (2012) Efficacy and Safety of Neoadjuvant Pertuzumab and Trastuzumab in Women with Locally Advanced, Inflammatory, or Early HER2-Positive Breast Cancer (NeoSphere): A Randomised Multicentre, Open-Label, Phase 2 Trial. The Lancet Oncology, 13, 25-32. https://doi.org/10.1016/S1470-2045(11)70336-9
|
[27]
|
Llombart-Cussac, A., et al. (2017) HER2-Enriched Subtype as a Predictor of Pathological Complete Response Following Trastuzumab and Lapatinib without Chemotherapy in Ear-ly-Stage HER2-Positive Breast Cancer (PAMELA): an Open-Label, Single-Group, Multicentre, Phase 2 Trial. The Lan-cet Oncology, 18, 545–554.
https://doi.org/10.1016/S1470-2045(17)30021-9
|
[28]
|
Rimawi, M.F., et al. (2013) Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab with Hormonal Therapy and without Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: TBCRC 006. Journal of Clinical Oncology, 31, 1726-1731. https://doi.org/10.1200/JCO.2012.44.8027
|
[29]
|
Untch, M., Rezai, M., Loibl, S., et al. (2010) Neoad-juvant Treatment with Trastuzumab in HER2-Positive Breast Cancer: Results from the GeparQuattro Study. Journal of Clinical Oncology, 28, 2024-2031.
https://doi.org/10.1200/JCO.2009.23.8451
|
[30]
|
Gianni, L., Eiermann, W., Semiglazov, V., et al. (2010) Neoadju-vant Chemotherapy with Trastuzumab Followed by Adjuvant Trastuzumab versus Neoadjuvant Chemotherapy Alone, in Patients with her2positive Locally Advanced Breast Cancer (the NOAH trial): A Randomised Controlled Superiority Tri-al with a Parallel HER2negative Cohort. The Lancet, 375, 377-384. https://doi.org/10.1016/S0140-6736(09)61964-4
|
[31]
|
Cameron, D., et al. (2017) 11 Years’ Follow-Up of Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Early Breast Cancer: Final Analysis of the HERceptin Ad-juvant (HERA) Trial. The Lancet, 389, 1195-1205.
https://doi.org/10.1016/S0140-6736(16)32616-2
|
[32]
|
Perez, E.A., et al. (2014) Trastuzumab Plus Adjuvant Chem-otherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival from NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology, 32, 3744-3752. https://doi.org/10.1200/JCO.2014.55.5730
|
[33]
|
Swain, S.M., et al. (2015) Pertuzumab, Trastuzumab and Docet-axel in HER2-Positive Metastatic Breast Cancer. The New England Journal of Medicine, 372, 724-734. https://doi.org/10.1056/NEJMoa1413513
|
[34]
|
Hurvitz, S.A., Martin, M., Symmans, W.F., et al. (2018) Neoadju-vant Trastuzumab, Pertuzumab and Chemotherapy versus Trastuzumab Emtansine Plus Pertuzumab in Patients with HER-2-Positive Breast Cancer (KRISTINE): A Randomised, Open-Label, Multicentre, Phase 3 Trial. The Lancet On-cology, 19, 115-126.
https://doi.org/10.1016/S1470-2045(17)30716-7
|
[35]
|
Gallagher, C.M., More, K., Masaquel, A., et al. (2016) Sur-vival in Patients with Non-Metastatic Breast Cancer Treated with Adjuvant Trastuzumab in Clinical Practice. Springer-plus, 5, Article No. 395.
https://doi.org/10.1186/s40064-016-2008-9
|
[36]
|
Ali, S., Hendry, J., Le, D., Mondal, P.K., Sami, A., Chalchal, H., Haider, K., Ahmed, O., El-Gayed, A., Wright, P., Pauls, M., Johnson, K. and Ahmed, S. (2022) Efficacy of Adjuvant Trastuzumab in Women with HER2-Positive T1a or bN0M0 Breast Cancer: A Population-Based Cohort Study. Scientific Reports, 12, Article No. 1068.
https://doi.org/10.1038/s41598-022-05209-8
|
[37]
|
Piccart-Gebhart, M., Holmes, E., Baselga, J., et al. (2016) Adju-vant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2positive Breast Cancer: Results from the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. Journal of Clinical Oncology, 34, 1034-1042.
https://doi.org/10.1200/JCO.2015.62.1797
|
[38]
|
Slamon, D.J., Leyland-jones, B., Shak, S., et al. (2001) Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer that Overexpresses HER2. The New England Journal of Medicine, 344, 783-792.
https://doi.org/10.1056/NEJM200103153441101
|
[39]
|
Marty, M., Cognetti, F., Maraninchi, D., et al. (2005) Ran-domized Phase Iitrial of the Efficacy and Safety of Trastuzumab Combined with Docetaxel in Patients with Human Epi-dermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Administered as First-Line Treatment: The M77001 Study Group. Journal of Clinical Oncology, 23, 4265-4274. https://doi.org/10.1200/JCO.2005.04.173
|
[40]
|
Giordano, S.H., Temin, S., Kirshner, J.J., et al. (2014) Systemic Therapy for Patients with Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American So-ciety of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 32, 2078-2099. https://doi.org/10.1200/JCO.2013.54.0948
|
[41]
|
Bachelot, T., Ciruelos, E., Schneeweiss, A., et al. (2019) Prelimi-nary Safety and Efficacy of First-Line Pertuzumab Combined with Trastuzumab and Taxane Therapy for HER2-Positive Locally Recurrent or Metastatic Breast Cancer (PERUSE). Annals of Oncology, 30, 766-773. https://doi.org/10.1093/annonc/mdz061
|
[42]
|
Robert, N., Leyland-jones, B., Asmar, L., et al. (2006) Randomized Phase III Study of Trastuzumab, Paclitaxel and Carboplatin Compared with Trastuzumab and Paclitaxel in Women with HER-2-Overexpressing Metastatic Breast Cancer. Annals of Oncology, 24, 2786-2792. https://doi.org/10.1200/JCO.2005.04.1764
|